Disappointing study results for Menlo Therapeutics

Menlo Therapeutics Inc. (Nasdaq: MNLO) reported disappointing results from a Phase 2 clinical trial of serlopitant to treat pruritus in adults and adolescents with a history of atopic dermatitis. Shares of the biopharmaceutical collapsed $27.05 to close at $8.17.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.